Chronic Spontaneous Urticaria Endotypes: Exploratory Proteomic Analysis in the Benralizumab <scp>ARROYO</scp> Study
Clinical & Experimental Allergy, 2026
Rodríguez‐Suárez E., Cardner M., Muthas D., Chamberlain C., Platt A., Altrichter S., Beck L., Bernstein J., Giménez‐Arnau A., Metz M., McCrae C.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Immunological & Inflammatory Diseases Dermatological Diseases | Pathophysiology Patient Stratification | Plasma |  Olink Explore 3072/384 |
Abstract
In this post hoc analysis funded by AstraZeneca, benralizumab reduced eosinophil‐related protein biomarker expression. Benralizumab reduced eosinophil‐derived neurotoxin concentrations, which were dose‐independent and irrespective of BHRA status.